Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

the interpretation was that the low albumin and proteinuria likely represented nephrotic syndrome and that this argued for the possibility of class V lupus nephritis or the membranous lupus lesion.

The drug is also in mid-stage clinical trials for primary membranous nephropathy (PMN) and antibody-mediated transplant rejection and is in phase 1 for lupus nephritis. According to the American ...

Specifically, this antibody has been used to treat membranous nephropathy, cryoglobulinemic glomerulonephritis, systemic lupus erythematosus (SLE) and ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA ...

Methods: Google Trends™ were used to analyze search activity from January 2004 to December 2024 for IgA nephropathy (IgAN), membranous glomerulonephritis (MN), focal segmental glomerulosclerosis (FSGS ...

antibody positive and membranous glomerulonephritis (membranous nephropathy), lupus nephritis and Sjogren's syndrome and COVID-19 mediated postural orthostatic tachycardia syndrome. It is also under ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...